ANDA 210826, held by Aurobindo Pharma Ltd. Levomilnacipran Hydrochloride.
As of Nov 16, 2026, ANDA 210826 (Levomilnacipran Hydrochloride), held by Aurobindo Pharma Ltd, was first approved by FDA on Jan 6, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 6, 2023 | Original application | Approved | None posted |
| Levomilnacipran HydrochlorideEQ 20MG BASE · capsule, extended release;oral | Levomilnacipran Hydrochloride | Discontinued |
| Levomilnacipran HydrochlorideEQ 40MG BASE · capsule, extended release;oral | Levomilnacipran Hydrochloride | Discontinued |
| Levomilnacipran HydrochlorideEQ 80MG BASE · capsule, extended release;oral | Levomilnacipran Hydrochloride | Discontinued |
| Levomilnacipran HydrochlorideEQ 120MG BASE · capsule, extended release;oral | Levomilnacipran Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters